Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: LzzrdKing who wrote (7154)	8/19/1999 8:36:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 7396

UTHR--The next event that matters for UTHR is the ESC (European Society of Cardiology) meeting in Barcelona, August 28-Sept 1. Dr. Stuart Rich, who is one of the foremost experts in the world on pulmonary hypertension, will be giving the talk on UT-15, UTHR's lead product. What is important is to learn how this product compares to a less stable product put out by Glaxo Wellcome called Flolan. Flolan is currently on the market, but this new analog of a naturally occurring compound called prostacyclin put out by UTHR is supposed to be (1) more effective and (2) easier to use. If UT-15 is successful it could generate at least 250 million in annual sales. There are other UTHR"s products such as Beraprost for the treatment of peripheral vascular disease which could further enhance sales. But one thing at a time, Spain is where it is at for any UTHR holders at this point. (Personal note to the thread: yes, I was a College chemistry major.)